| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Niagen Bioscience, Inc. (NAGE) has 8 insiders with recent SEC Form 4 filings, including 3 buys and 1 sell. NAGE is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Dir | 20.0K | $68.2K | - | |
| Dir | 20.0K | $68.2K | - | |
| Dir | 20.0K | $68.2K | - | |
| Dir | 20.0K | $68.2K | - | |
| Dir | 20.0K | $68.2K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Sep 1, 2016 | Jaksch Frank L Jr | CEO, President | Buy | 1,500 | $3.32 | $4,980.00 | +0.8% | |
| Jun 20, 2016 | Rhonemus Troy Allen | Chief Operating Officer | Buy | 7,800 | $3.47 | $27,083.60 | +52.0% | |
| Jan 29, 2016 | Fried Robert N51 | Director | Sell | 5,063 | $1.26 | $6,379.38 | -3.1% |